PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy

• DOI: 10.1007/s13346-024-01557-2
• Publication Date: 2024-03-01T14:02:01Z
• Authors: Lorena Gonzalez-M...; Edorta Santos-Viz...; Ruben Varela-Calvino; Iria Gomez-Tourino; Aintzane Asumendi; Maria Dolores Boyano; Manoli Igartua; Rosa Maria Hernandez
• Keywords: PLGA; Cancer Immunotherapy

Melanoma is the main cause of death among skin cancers and its incidence worldwide has been experiencing an appalling increase. However, traditional treatments lack effectiveness in advanced or metastatic patients. Immunotherapy, meanwhile, shown to be effective treatment option, but rate responding remains far from ideal. Here we have developed a personalized neoantigen peptide-based cancer vaccine by encapsulating patient derived melanoma neoantigens polyethylenimine (PEI)-functionalised poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) coating them with polyinosinic:polycytidylic acid (poly(I:C)). We found that PLGA NPs can effectively modified coated immunoadjuvant poly(I:C), as well encapsulate neoantigens. In addition, both dendritic cells (DCs) lymphocytes were stimulated. Moreover, NP was better immune activation profile than without poly(I:C) antigen. Our results demonstrate high capacity activate system, efficiently maturing DCs present antigen choice promoting activity exert their cytotoxic function. Therefore, response generated optimal specific for elimination tumour cells.